Overview

Hexagon Bio uses synthetic biology and data science to discover and develop new medicines by analyzing genomic data from thousands of species to find small molecules that inhibit disease-related proteins. Its proprietary algorithm searches genomes to identify lead compounds and its platform can quickly turn those molecules into candidates suitable for clinical development. The company blends computational biology, chemistry, and synthetic biology to move from genome data to drug candidates faster, and it leverages inexpensive sequencing to access diverse genetic information while producing leads in-house. Its goal is to build a steady pipeline of drug candidates and license them to larger pharmaceutical companies to advance through clinical trials and commercialization.